Faculty Earn State Grants for Cancer Research

A person in a lab.
September 21, 2022
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism

A man smiling in a research lab.
September 7, 2021
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.

Improving Health Outcomes for People Experiencing Homelessness is Focus of New Study

Five people holding cell phones and wearing masks.
April 30, 2021
Combining mobile health technology, or mHealth, and community outreach to improve the health outcomes of people experiencing homelessness is the target of a new study led by Division of Health Outcomes Associate Professor Leticia Moczygemba, Pharm.D., Ph.D., thanks to a five-year research grant from the U.S. Department of Health and Human Services Agency for Healthcare Research and Quality.

TxCORE Research Wins PhRMA Foundation Award

Three people smiling.
April 1, 2021
Three researchers from the College of Pharmacy won an award from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. Leticia R. Moczygemba, Pharm.D., Ph.D., Carolyn M. Brown, Ph.D. and Michael Johnsrud, Ph.D., R.Ph. were awarded $5,000 from the PhRMA Foundation for their proposal to advance racial and ethnic representation in value assessments.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.

Mukhopadhyay Wins Research Excellence Award

A man standing in a research laboratory.
September 10, 2020
Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.

New Delivery Method Could Make Niclosamide an Effective Antiviral to Treat COVID-19

Two men in suits smiling.
April 6, 2020
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.

Existing drug may help fight against the lethality of E. coli infection

Som figure
June 26, 2019
New research from the lab of Division of Pharmacology and Toxicology’s Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. may have discovered a way to repurpose an existing drug to fight the lethality of Shiga toxin-producing Escherichia coli (STEC) infections.